Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹14 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹0 Cr
ROE
0 %
ROCE
0 %
P/E Ratio
--
P/B Ratio
1.6
Industry P/E
--
EV/EBITDA
13773.1
Div. Yield
0 %
Debt to Equity
0
Book Value
₹--
EPS
₹0
Face value
1
Shares outstanding
100,000,000
CFO
₹-0.12 Cr
EBITDA
₹-0.14 Cr
Net Profit
₹0.08 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Safal Herbs
| 106.0 | 89.0 | 70.4 | -32.4 | -28.6 | -45.2 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|---|
|
Safal Herbs
| -42.2 | -64.2 | -35.4 | -50.0 | -77.9 | 59.5 |
|
BSE Sensex
| 14.4 | 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| -3.5 | -5.9 | 0.5 | -12.9 | 15.1 | 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Safal Herbs
|
1.4 | 13.8 | 0.3 | 0.0 | -25.3 | -- | -- | 1.6 |
| 27.0 | 15.4 | 8.0 | 0.6 | 13.8 | 5.5 | 24.4 | 1.2 | |
| 12.0 | 7.1 | 2.6 | 0.1 | -- | 1.2 | 89.8 | 0.9 | |
| 606.6 | 7,530.1 | 469.1 | 90.7 | -- | 39 | 83 | 17.9 | |
| 189.3 | 246.0 | 127.7 | -24.3 | -20.8 | -325.5 | -- | 49.3 | |
| 24.8 | 42.5 | 49.3 | 0.8 | 1.6 | 4.5 | 55.9 | 2.5 | |
| 32.4 | 31.3 | 67.2 | 2.1 | 3.3 | 4.9 | 15.3 | 0.9 | |
| 167.4 | 263.5 | 162.9 | 9.8 | -- | 32.2 | 26.8 | 5.1 | |
| 114.3 | 73.5 | 65.4 | 2.8 | 6.6 | 12.1 | 26.4 | 3.0 | |
| 191.0 | 200.8 | 89.9 | 7.2 | -- | 13.7 | 28.1 | 3.2 |
No Review & Analysis are available.
Manufacture of ayurvedic' or unani' pharmaceutical preparation
Incorporated
1994
Chairman
--
Managing Director
Arushi Nigam
Headquarters
Delhi, Delhi
Website
--
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsShareholding for the Period Ended June 30 2021
16-Nov-2021Shareholding for the Period Ended March 31 2021
16-Nov-2021Shareholding for the Period Ended June 30 2020
16-Nov-2021Shareholding for the Period Ended March 31 2020
16-Nov-2021
The share price of Safal Herbs Ltd is ₹1.38 (BSE) as of 11-Mar-2020 IST. Safal Herbs Ltd has given a return of -28.59% in the last 3 years.
Since, TTM earnings of Safal Herbs Ltd is negative, P/E ratio is not available.
The P/B ratio of Safal Herbs Ltd is 1.57 times as on 11-Mar-2020, a 97 discount to its peers’ median range of 49.27 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2020
|
7,365.11
|
1.57
|
|
2019
|
0.00
|
1.99
|
|
2018
|
0.00
|
3.17
|
|
2017
|
2,707.14
|
4.28
|
|
2016
|
6,807.06
|
8.57
|
The 52-week high and low of Safal Herbs Ltd are Rs -- and Rs -- as of 05-Apr-2026.
Safal Herbs Ltd has a market capitalisation of ₹ 14 Cr as on 11-Mar-2020. As per SEBI classification, it is a company.
Before investing in Safal Herbs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.